Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: December 2, 2021

DrugPatentWatch Database Preview

Patent: 10,526,382

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,526,382
Title:Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof
Abstract: The present disclosure provides hNGAL muteins that bind Ang-2 and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.
Inventor(s): Bel Aiba; Rachida SIham (Munich, DE), Allersdorfer; Andrea (Wolnzach, DE), Wiedenmann; Alexander (Ulm, DE), Rothe; Christine (Dachau, DE), Olwill; Shane (Freising, DE), Gille; Hendrik (Berlin, DE), Audoly; Laurent (Toulouse, FR)
Assignee: Pieris Pharmaceuticals GmbH (Freising-Weihenstephan, DE)
Application Number:15/546,609
Patent Claims:see list of patent claims

Details for Patent 10,526,382

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 2004-02-26 ⤷  Free Forever Trial 2035-01-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.